International
The Morning Science

What science found today

‹
 

Research

BT-115386, a MAT2A inhibitor, targets MTAP-deficient nasopharyngeal carcinoma via c-Myc and p53 modulation

Cell Reports Medicine · By Yuk-Yu Chan, Man Wu, Grace Tin Yun Chung, Yi Zhang, Ming-Ting Liu, Xiaodong Zhang, Qian Wu, Shinyee Hui, Bo Wang, Eeling Kong, Melissa Sue Ann Chan, Hei-Man Leung, Ying Cong, Ka-Fai To, David Johnson, Brigette Buig Yue Ma, Jun Tang, Kwok-Wai Lo & Chi-Man Tsang ·

The Brief

  • MTAP homozygous deletion occurs in 37.5% of Epstein-Barr virus-associated nasopharyngeal carcinomas, according to the source.
  • Chan et al. report that the oral MAT2A inhibitor BT-115386 achieved robust tumor suppression in nasopharyngeal carcinoma.
  • The authors state that BT-115386 works by targeting PRMT5 to degrade c-Myc and restore p53 signaling.

Why it matters

The study points to MTAP deficiency as a possible patient-selection marker for MAT2A or PRMT5-pathway drugs in a cancer type where it is common. Readers should note that the source describes the mechanism but does not report clinical outcomes.

Who’s affected

  • cancer researchers studying nasopharyngeal carcinoma
  • oncology drug developers working on MTAP-deficient tumors

MTAP homozygous deletion occurs in 37.5% of Epstein-Barr virus-associated nasopharyngeal carcinomas (NPCs). Chan et al. demonstrate that the oral MAT2A inhibitor BT-115386 achieves robust tumor suppression by targeting PRMT5 to degrade c-Myc and restore p53 signaling in NPC…

Timeline

  1. Study published in Cell Reports Medicine

  2. cell.com

    BT-115386, a MAT2A inhibitor, targets MTAP-deficient nasopharyngeal carcinoma via c-Myc and p53 modulation

How do you feel about this?

0 Comments

    BT-115386, a MAT2A inhibitor, targets MTAP-deficient nasopharyngeal carcinoma via c-Myc and p53 modulation – The Morning Science